<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895007</url>
  </required_header>
  <id_info>
    <org_study_id>2021-04-30T1</org_study_id>
    <nct_id>NCT04895007</nct_id>
  </id_info>
  <brief_title>Comparative Evaluation of Covid-19 Vaccines Response</brief_title>
  <official_title>Comparative Evaluation of Covid-19 Vaccines Response and Progression in Different Covid-19 Vaccines Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karamanoğlu Mehmetbey University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karamanoğlu Mehmetbey University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Population&#xD;
&#xD;
      Population with vaccinated with three different Covid Vaccines (Inactive Vaccine (Sinovac&#xD;
      Life Sciences, Beijing, China), recombinant human adenovirus serotype number 26 (rAd26 of&#xD;
      Sputnik V), mRNA Vaccine (Pfizer/BionTEC). This is multi center study, 5 centers will be&#xD;
      joined to study from different part of the country. Approximately 1500 people will be&#xD;
      enrolled to study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of Study&#xD;
&#xD;
        -  to evaluate Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody response in different&#xD;
           Vaccine Groups&#xD;
&#xD;
        -  to evaluate progression of the vaccine response after 2, 6, and 12 Months after&#xD;
           Vaccination in different Vaccine Groups, and compare antibody response in different&#xD;
           Vaccines Group.&#xD;
&#xD;
        -  It was also aimed to evaluate effect of the age, gender, co-morbid conditions such as&#xD;
           COPD, DM, Heart Failure, Covid Infection on IgG Antibody and Neutralizing Antibody&#xD;
           response.&#xD;
&#xD;
      Anti SARS CoV2 IgG antibody levels will be measured with chemiluminescence method (CHEM) by&#xD;
      using ADVIA Centaur XP Immunassay System (Siemens Helthcare, GmbH, Germany) and Anti SARS&#xD;
      CoV2 IgG reactive (Siemens Helthineers, GmbH, Germany).&#xD;
&#xD;
      Neutralizing Capacity of Anti-SARS-CoV-2 Antibodies against SARS CoV2 levels will be&#xD;
      determined with ELISA method (ELx 808, ELISA Microplate Absorbance Reader, BioTek Instruments&#xD;
      Inc, Winooski, VT, USA) by using Euroimmun SARS-CoV-2 NeutraLISA Assay (EUROIMMUN,&#xD;
      Medizinische Labordiagnostika AG, Germany).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody at 12 months</measure>
    <time_frame>12 Months</time_frame>
    <description>Baseline Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody levels at 14th day after second dose&#xD;
Change of Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody levels at 3 Months after second dose&#xD;
Change of Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody levels at 6 Months after second dose&#xD;
Change of Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody levels at 12 Months after second dose</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>COVID-19 Vaccines</condition>
  <arm_group>
    <arm_group_label>Group, vaccinated with Inactive Vaccine (Sinovac Life Sciences, Beijing, China).</arm_group_label>
    <description>- Any person, male or female, over 18 years of age, were vaccinated with Inactive Vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group, vaccinated with recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V).</arm_group_label>
    <description>- Any person, male or female, over 18 years of age, were vaccinated with recombinant human adenovirus serotype number 26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group, vaccinated with mRNA Vaccine (Pfizer/BionTEC).</arm_group_label>
    <description>- Any person, male or female, over 18 years of age, were vaccinated with mRNA Vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine</intervention_name>
    <description>Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.</description>
    <arm_group_label>Group, vaccinated with Inactive Vaccine (Sinovac Life Sciences, Beijing, China).</arm_group_label>
    <arm_group_label>Group, vaccinated with mRNA Vaccine (Pfizer/BionTEC).</arm_group_label>
    <arm_group_label>Group, vaccinated with recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V).</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        - Any person, male or female, over 18 years of age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Any person, male or female, over 18 years of age.&#xD;
&#xD;
          1. The patient has signed an informed consent form.&#xD;
&#xD;
          2. The patient was vaccinated with SARS-CoV-2 vaccine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give clear information (person in an emergency, difficulty understanding&#xD;
             the subject, etc.)&#xD;
&#xD;
          -  Person under safeguard of justice&#xD;
&#xD;
          -  Person under guardianship or curator ship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karamanoglu Mehmetbey University</name>
      <address>
        <city>Karaman</city>
        <zip>70200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taha T Bekci, Prof.Dr.</last_name>
      <phone>+905333787676</phone>
      <email>doktortaha@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Selcuk University</name>
      <address>
        <city>Konya</city>
        <zip>42250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recep Kesli, Prof.Dr.</last_name>
      <phone>+905454605460</phone>
      <email>recepkesli@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tekirdag Namık Kemal University, Faculty of Medicine</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nejat Altıntas, Assoc.Prof.Dr.</last_name>
      <email>nejataltintas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technic University, Faculty of Medicine</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tevfik Ozlu, Prof.Dr.</last_name>
      <email>ozlutevfik@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karamanoğlu Mehmetbey University</investigator_affiliation>
    <investigator_full_name>Prof.Dr.Taha Bekci</investigator_full_name>
    <investigator_title>Head of Pulmonary Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

